Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

Panelists summarize key takeaways on using bispecific antibodies for multiple myeloma treatment.

EP: 1.Impact of Bispecific Antibodies on Multiple Myeloma Treatment

EP: 2.Key Considerations in Treatment Selection for Patients With Multiple Myeloma

EP: 3.Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody

EP: 4.Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies

EP: 5.The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies

EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma

EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma

EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma

EP: 9.Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma

EP: 10.Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM

EP: 11.Complying with REMS Training and Documentation Requirements

EP: 12.Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM

EP: 13.Unmet Needs in Multiple Myeloma Care

EP: 14.Treatment Sequencing and Combination Therapies for MM

Now Viewing

EP: 15.Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

EP: 16.Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma

EP: 17.Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials

EP: 18.Identifying Patients Who Are Candidates for Bispecifics and Referring Patients for Care

EP: 19.Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics

EP: 20.Considerations for Maintenance Therapy in the Community Oncology Setting

EP: 21.Team Approach to Meeting REMS Program Requirements

EP: 22.Role of Pharmacists in Operationalizing Bispecific Antibodies

EP: 23.Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting

EP: 24.Unmet Needs in Relapsed or Refractory Multiple Myeloma

Related Videos

Related Content

Advertisement

April 30th 2025

AACR 2025: Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma

Alana Hippensteele, Lead Editor

January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor

April 4th 2025

Caveolin-1 May Be A Promising Therapeutic Target For Multiple Myeloma, Study Finds

Alexandra Gerlach, Associate Editor

April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

March 26th 2025

Long-Term Follow-Up Data from the CASSIOPEIA Trial Show Continued MRD, PFS Benefit in Multiple Myeloma

Alexandra Gerlach, Associate Editor

March 21st 2025

BCMA-Targeting CAR T-Cell Therapy Is Feasible in Patients With Multiple Myeloma and CNS Involvement

Alexandra Gerlach, Associate Editor

Related Content

Advertisement

April 30th 2025

AACR 2025: Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma

Alana Hippensteele, Lead Editor

January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor

April 4th 2025

Caveolin-1 May Be A Promising Therapeutic Target For Multiple Myeloma, Study Finds

Alexandra Gerlach, Associate Editor

April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

March 26th 2025

Long-Term Follow-Up Data from the CASSIOPEIA Trial Show Continued MRD, PFS Benefit in Multiple Myeloma

Alexandra Gerlach, Associate Editor

March 21st 2025

BCMA-Targeting CAR T-Cell Therapy Is Feasible in Patients With Multiple Myeloma and CNS Involvement

Alexandra Gerlach, Associate Editor